We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Sentinel Node Biopsy: Facts to Clear the Alleged Clouds

Donald L. Morton, MD; Robert Elashoff, PhD
Arch Dermatol. 2008;144(5):685-686. doi:10.1001/archderm.144.5.685.
Text Size: A A A
Published online


Sentinel node biopsy (SNB) was developed to identify the 20% of patients with intermediate-thickness primary melanoma (1.2-3.5 mm) and regional nodal metastasis who might benefit from lymphadenectomy before, rather than after, clinical nodal recurrence.1 Our group's randomized international study of the diagnostic utility and prognostic significance of SNB2 was unjustly criticized by González.3 His commentary wrongly claims that our abstract did not include overall results. Although it is not customary to expect survival benefits for a staging and/or diagnostic procedure,4,5 we reported the overall impact of SNB on survival. Our group clearly states in the abstract2(p1307) that the mean estimated 5-year disease-free survival was 78.3% with SNB vs 73.1% with observation (hazard ratio, 0.74; P = .009). Five-year melanoma-specific survival rates were 87.1% and 86.6%, respectively.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Melanoma-specific survival in patients with nodal metastases. Numbers indicate subgroups. Subgroup 1 includes patients with a tumor-positive sentinel node, and subgroup 4 includes patients with nodal recurrence despite a negative finding on sentinel node biopsy. Subgroup 2 includes all patients in subgroups 1 and 4. Subgroup 3 includes patients with nodal recurrence during observation. Figure reproduced from Morton et al2 with permission.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

7 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
PubMed Articles